AUPH — Q2 2026 Financial Report Analysis

LUPKYNIS sales up 19%, and profit up even faster, partly for reasons that won't repeat

Aurinia sells one drug: LUPKYNIS (voclosporin), a twice-daily pill for lupus nephritis, the kidney inflammation that affects many people with lupus. In the second quarter of 2026 (April–June), LUPKYNIS net product sales (what Aurinia actually collects after discounts and rebates) rose 19% to $79.4 million. Management attributes this to "an increase in the number of LUPKYNIS cartons sold to specialty pharmacies, driven by further lupus nephritis market penetration". In other words, more patients on the drug, not price. Total revenue rose 19% to $83.2 million. Operating income more than doubled, from $20.1 million to $46.3 million. About half of that jump came from items outside the drug business: a currency gain where last year there was a currency loss, and a lower stock-compensation charge after executives left.

At a glance

• $79.4M LUPKYNIS sales, +19% year on year and +8% on Q1's $73.6M. Demand is still growing. The drug's growth hasn't flattened out five years after launch.
• 55.7% operating margin, up from 28.7%. Excluding the swing in "other (income) expense" (mostly currency moves), the margin was about 48%, against about 42% a year ago. Still a real improvement, but a smaller one.
• $0.28 diluted EPS, +75%, even though the tax rate jumped from 2.9% to 23.3%. Pre-tax income rose 120%. A higher, more normal tax bill absorbed part of that.

The numbers

For the first half, revenue was $160.9 million (+21%), LUPKYNIS sales $153.0 million (+21%), net income $71.8 million (+60%) and diluted EPS $0.53 (+66%).

What drove the quarter

LUPKYNIS volume. Sales grew $12.8 million year on year, and the 10-Q credits it to more cartons sold. Cost of revenue (manufacturing and supply) fell 7% to $6.6 million. According to the company, that was "primarily due to a decrease in sales of LUPKYNIS inventory to Otsuka, which has a low gross margin." Otsuka is Aurinia's partner outside the US. So the improvement in gross margin comes partly from a mix shift away from that low-margin partner business. It isn't only higher US prices or volumes.

Collaboration revenue rose to $3.8 million. The filing attributes it mainly to "manufacturing services provided to Otsuka for sharing the capacity of the Monoplant," the dedicated voclosporin manufacturing facility Aurinia leases in Switzerland.

Spending moved in opposite directions. SG&A (selling, general and administrative costs: the sales force, marketing and head office) fell $2.5 million. Almost all of the drop is in share-based pay: the SG&A stock-compensation charge was $1.2 million against $4.9 million a year ago. The company says this was because of lower charges "related to the departures of certain former Company officers in March 2026" and a reversal of expense on forfeited unvested awards. Professional fees actually rose $1.4 million. R&D (research and development) rose 76% to $13.1 million. R&D staff costs roughly tripled (from $1.7 million to $5.7 million) and clinical supply costs rose. This spending supports aritinercept, the company's pipeline drug, and a new LUPKYNIS study.

What the headline numbers hide

• About half of the operating-income jump isn't from the drug business. "Other (income) expense, net" was a $6.2 million gain in Q2 2026, against a $9.2 million cost in Q2 2025. That $15.5 million swing is a third of this year's operating income. The 10-Q gives three reasons. First, currency: the Monoplant lease is a liability priced in Swiss francs, so the dollar value Aurinia owes moves with the exchange rate. That was a large loss last year and a small gain this year. Second, a one-time payment that settled all future obligations under one arrangement. Third, a lower accrual for shareholder matters. Excluding this line and last year's $0.1 million restructuring charge, operating income rose about 36%, from roughly $29.4 million to $40.1 million. That's still nearly twice the pace of revenue growth, but well short of the reported +131%.
• Lower SG&A partly reflects stock-pay reversals. Stock-based pay in SG&A was $1.2 million this quarter, and only $31 thousand for the whole first half (against $1.4 million a year ago), because awards of departed officers were forfeited and their expense reversed. The first half also carried one-time severance for those officers, booked in Q1. Neither effect will recur, so expect underlying SG&A to run somewhat higher.
• The tax change: EPS would have grown faster at a constant tax rate, and the extra tax is mostly not cash. Aurinia released the rest of its "valuation allowance" in Q4 2025. That's an accounting reserve against past losses, so those losses now sit on the balance sheet as a deferred tax asset (a credit against future taxes). From 2026, profits carry a normal-looking 23.3% tax charge instead of the near-zero rate of 2025. But $20.4 million of the $20.9 million first-half tax expense was deferred, meaning it drew down that asset rather than going to a tax authority. Pre-tax income rose 120%, but net income only 74%. Cash taxes remain small for now.
• Cash conversion was strong. Operating cash flow was $52.5 million in Q2 against $37.4 million of net income. For the half it was $85.1 million, up 87%. Receivables ($41.1M) and inventory ($45.2M) were both slightly lower than at December 31 even as sales grew. That's the opposite of the warning sign where receivables grow faster than sales.
• Buybacks helped EPS less than the dollar figure suggests. Aurinia spent $74.9 million repurchasing 5.0 million shares in the first half. Option exercises and other equity awards brought in $59.2 million and added shares, though. Shares outstanding rose from 132.3 million to 132.9 million over the half. The diluted share count used for EPS was 2.9% lower than a year ago. So buybacks explain only a small part of the 75% EPS increase. The rest is higher operating profit and the currency swing.
• Guidance unchanged. Management "reiterates" full-year guidance. That's neither a raise nor a cut, even after a quarter above the implied run rate.

Takeaway: LUPKYNIS is still adding patients. Sales grew 19% with lower cost of revenue, and the underlying operating margin widened from about 42% to 48%. Still, about half of the reported doubling in operating income came from a Swiss-franc currency swing and one-off liability releases. The reported 55.7% margin should not be treated as the new normal.

Two non-financial events that matter

Kezar acquisition (closed May 11, 2026). Aurinia bought Kezar Life Sciences for $6.955 per share in cash plus one contingent value right (CVR) per share. A CVR is an IOU that pays former Kezar holders more only if certain things happen. Here those are milestones for Kezar's drug zetomipzomib, certain proceeds from Kezar's past partnerships, and any Kezar cash above $50 million at closing. Total consideration was $55.5 million, of which $51.6 million was paid in cash. Kezar brought $56.8 million of cash with it. So the deal was close to cash-neutral: Aurinia's cash flow statement shows $5.2 million of net cash acquired. Accounting treated it as an asset purchase, not a business acquisition. Only $0.4 million of purchased research was expensed, and Kezar's US tax attributes may reduce future US tax.

Teva patent settlement (August 19, after quarter end). Teva, which had applied to sell a generic voclosporin, agreed that two Aurinia patents expiring December 2037 are valid and would be infringed. Teva can't launch before December 7, 2036, "unless certain defined contingencies occur earlier". These contingency clauses are typical in such settlements and usually let the generic launch early if another generic enters first. Lawsuits against six other would-be generic makers (DifGen, Dr. Reddy's, Hikma, Lotus, Sandoz and Zydus) are still pending. One settlement is a good sign. It doesn't yet protect the drug's US exclusivity on its own.

Outlook

Management guidance (2026): total revenue of $315–325 million (+11% to +15% vs 2025) and LUPKYNIS net product sales of $305–315 million (+12% to +16%), both reiterated. With $153.0 million of product sales already booked in the first half, the range implies $152–162 million in the second half, or about $76–81 million a quarter. Q2's $79.4 million already sits near the top of that band. Holding Q2's level would put the year near the guidance top. Any sequential growth would beat it. The 10-Q also says R&D "expense [will] increase as we progress our development activities."

Pipeline: Aurinia has started PRESERVE, a Phase 4 (post-approval) study of about 150 patients. It tests LUPKYNIS alongside three biologic lupus drugs: belimumab, obinutuzumab and anifrolumab. The main measure is complete kidney response at six months. Aritinercept blocks two immune signals, BAFF and APRIL, that keep antibody-producing B cells alive. It is now in clinical development for four potential indications. No efficacy data is in this filing.

Our view: The core business is growing at about 19% a year. It has a gross margin above 90% and generated $85 million of operating cash in six months, with $443.1 million of cash and investments and no debt beyond the Monoplant lease. Two things to watch in Q3, due around early November. First, whether LUPKYNIS sales hold at or above $79 million, which would make the reiterated guidance look conservative. Second, how much R&D rises as aritinercept trials enroll. For EPS, the currency line can swing either way by several million dollars a quarter, and the stock-comp reversals won't repeat. So Q3 operating margin will likely come in below 55.7% even if the drug business keeps improving.

Note: this analysis covers the quarter ended June 30, 2026 (Form 10-Q filed August 6, 2026); the Teva settlement is from the company's August 19, 2026 Form 8-K.